Thandeka Moyo-Gwete
National Health Laboratory Service
South Africa
About
No AI summary yet.
Metrics
- Publications
- 47
- Citations
- 3.1K
- h-index
- 18
- Publishing journals
- 29
- Years of publications
- 12
- Active since
- 2014
- References
- 2.3K
- Institutions
- 6
Publication history
Latest publications
- Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance
- Population shift in antibody immunity following the emergence of a SARS-CoV-2 variant of concern
- Copper pincer targets SARS-CoV-2 Omicron, Delta, and Wild-Type receptor binding domains
- Randomised Trial of a Single Dose of Ad26.COV2.S, BNT162b2 or SARS-CoV-2-rS-PN in Previously Vaccinated and Unvaccinated Adults Living with and without HIV in South Africa: Safety and Immunogenicity
- Comparing the immune abnormalities in MIS-C to healthy children and those with inflammatory disease reveals distinct inflammatory cytokine production and a monofunctional T cell response
- Distinct T cell polyfunctional profile in SARS-CoV-2 seronegative children associated with endemic human coronavirus cross-reactivity
- Safety and immunogenicity of booster vaccination and fractional dosing with Ad26. COV2.S or BNT162b2 in Ad26.COV2.Svaccinated participants
- Evaluating the antibody response elicited by diverse HIV envelope immunogens in the African green monkey (Vervet) model
- Development of a Two-Component Nanoparticle Vaccine Displaying an HIV-1 Envelope Glycoprotein that Elicits Tier 2 Neutralising Antibodies
- Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination
- Infection pre-Ad26.COV2.S-vaccination primes greater class switching and reduced CXCR5 expression by SARS-CoV-2-specific memory B cells
- Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection
- T cell responses to SARS-CoV-2 spike cross-recognize Omicron
- SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape
- Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity.
- Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial)
- AstraZeneca COVID-19 vaccine induces robust broadly cross-reactive antibody responses in Malawian adults previously infected with SARS-CoV-2
- SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated individuals
- Author Correction: T cell responses to SARS-CoV-2 spike cross-recognize Omicron (Nature, (2022), 603, 7901, (488-492), 10.1038/s41586-022-04460-3)
- Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants
No publications in the index yet.